News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
MarketBeat Analyst action
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 5:00 p.m. ET CALL PARTICIPANTS Founder, Chairman and Chief Executive Officer - Charles Cohn Chief Financial Officer - Atul Bagga Associate General Counsel - T.J. Lynn Full Conference Call Transcript Operator: Good afternoon. …
Dr. Reddy’s Laboratories announced that Deepak Sapra, CEO of API & Services and a Senior Management Personnel, has resigned to pursue outside opportunities. His resignation is effective November 12, 2026, and he will remain with the company until then to ensure a smooth transition …
Shares of Dr. Reddy's Laboratories Ltd. (500124) increased by 0.59% to 1,206.00 Indian rupees on Thursday. This occurred during a positive trading session for the stock market, with the BSE SENSEX Index (1) rising by 0.15%. The company's shares closed 14.73% below their 52-week …
Dr. Reddy's Laboratories Ltd. shares fell 0.50% on Wednesday to 1,198.95 Indian rupees, underperforming the broader market as the BSE SENSEX Index dropped 0.24%. The company's stock closed 15.23% below its 52-week high achieved on June 29th.
Nerdy Inc. (NYSE:NRDY) saw its stock drop 11% after its second-quarter results, despite revenues aligning with predictions and smaller than expected statutory losses. Analysts have slightly increased optimism for loss per share but reduced revenue forecasts, leading to a 20% drop in the consensus …
Dr. Reddy's Laboratories Ltd (RDY) presents a potential 10.69% upside for investors, operating as a significant player in the drug manufacturing industry with a market capitalization of $10.18 billion. Despite this potential and a low forward P/E ratio, the company faces challenges including a …
Dr. Reddy's Laboratories Limited announced the termination of its distribution and promotion agreement with Novartis India Limited, effective September 30, 2026. This decision follows a change in the controlling shareholding of Novartis India. Dr. Reddy's will continue to commercialize the covered brands until the …
Shares of Dr. Reddy's Laboratories Ltd. fell by 1.25% on Monday, underperforming the broader market despite a favorable trading session where the BSE SENSEX Index rose. The company's stock closed at 1,157.35 Indian rupees, which is 18.17% below its 52-week high reached on June …
Key Points Interested in Nerdy Inc.? Here are five stocks we like better. Q2 performance improved: Revenue fell 4% year over year to $43.3 million, but gross margin expanded to 64.7%, net loss narrowed to $6.9 million, and adjusted EBITDA loss improved to $900,000. …
Dr. Reddy's Laboratories (500124) shares experienced a slight decline of 0.26% on Friday, closing at 1,172.00 Indian rupees, amidst a general downturn in the stock market where the BSE SENSEX Index (1) fell by 0.58%. Despite the dip, the company's performance still outpaced the …
Nerdy Inc. reported its second-quarter 2026 results, showing a revenue of $43.23 million, a 4.5% decrease year-over-year, and an improved diluted EPS of ($0.04). The company is experiencing a decline in active members and is winding down its Varsity Tutors for Schools business, but …
Nerdy, a St. Louis-based public company, is discontinuing its Varsity Tutors for Schools division and exiting its UK business, First Tutors. These strategic moves are projected to reduce the company's annual fixed costs by approximately $11 million.
Nerdy Inc (NRDY) has an earnings forecast score of 7.00, placing it 302nd in the Software & IT Services industry. Analysts have set an average price target of $1.62 with a "Buy" rating, projecting a 92.90% upside. The company's expected revenue for the next …
Nerdy (NYSE: NRDY) reported a narrowed Q2 2026 net loss of $6.9 million, down from $12.0 million year-over-year, driven by improved gross margins and reduced operating expenses. The company strategically exited its First Tutors business and plans to wind down Varsity Tutors for Schools, …
NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Dr. Reddy’s Laboratories (“Dr. Reddy’s” or the “Company”) (NYSE: RDY). The investigation concerns whether the Company and/or members of its senior management may have …
Dr. Reddy's Laboratories has launched Sugammadex Injection 200 mg/2 mL and 500 mg/5 mL Single-Dose Vials in the U.S., a generic equivalent of Bridion®. This first-to-market launch expands their hospital portfolio and aims to provide affordable, high-quality medicine. The product is indicated for reversing …
Sei Investments Co. significantly increased its stake in Dr. Reddy's Laboratories Ltd by 79.3% in the first quarter, now owning 436,731 shares valued at $6.05 million. Despite this, analyst sentiment for Dr. Reddy's remains negative, with several downgrades to "Sell" ratings and the company …
Dr. Reddy’s Laboratories has launched Sugammadex Injection Single-Dose Vials, a generic equivalent of Bridion, in the United States, coinciding with the first day of generic availability. This product is indicated for reversing neuromuscular blockade in adult and pediatric patients undergoing surgery. Bridion, the brand-name …
Dr. Reddy's Laboratories (NYSE: RDY) has received U.S. FDA approval for its rituximab biosimilar, a drug highly similar to Rituxan, intended for the U.S. market. This approval follows a successful Pre-License Inspection at their Hyderabad facility and marks a significant expansion of their global …
Dr. Reddy's Laboratories Ltd. shares increased by 1.94% on Monday, closing at 1,169.90 Indian rupees. This performance outperformed the overall market, as the BSE SENSEX Index rose by 0.70%. The company's stock closed 17.29% below its 52-week high.
Dr. Reddy's Laboratories has received USFDA approval for its rituximab biosimilar, a version of Rituxan, which expands its global biosimilars portfolio and strengthens its presence in the US market. The biosimilar, already commercialized in various regions including India and Europe, was developed, manufactured, and …
Dr Reddy's Laboratories had approximately 28,123 employees worldwide as of March 2026, representing a 3.0% growth from 2023. The company is actively hiring with 449 job postings in 2026 and its workforce is primarily concentrated in South Asia. The average salary is $16,666 globally, …
Lazard Asset Management LLC reduced its stake in Dr. Reddy's Laboratories (NYSE:RDY) by 9.3% in the first quarter, selling 108,731 shares. Despite this, several other institutional investors increased their holdings in the company. Analyst ratings for Dr. Reddy's Laboratories are predominantly "Reduce," with the …
Dr. Reddy’s Laboratories Ltd. anticipates a significant growth boost in the December and March quarters, following resolution of an impurity issue with its generic anti-obesity drug, semaglutide. The company expects to resume supply in early November, mitigating the impact of the issue on its …
Dr. Reddy’s Laboratories Limited announced that the USFDA completed a Pre-Approval Inspection (PAI) and Good Manufacturing Practices (GMP) inspection at its FTO-SEZ Process Unit-02 in Srikakulam, Andhra Pradesh, between July 20 and July 29, 2026. Following the inspection, the company received an FDA Form …
Search by ticker symbol or company name and select a result to open its chart.